sprouty related EVH1 domain containing 2Genealiases: NS14 · Spred-2
Q-omics provides the consensus-scored SPRED2 profile across patient tissues and cancer cell-line models. SPRED2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SPRED2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, SPRED2 RNA expression shows 20,251 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRP, HNSC, and BRCA as cancer lineages where SPRED2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPRED2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPRED2 survival associations across molecular data types. SPRED2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPRED2 RNA expression–survival associations across cancer types. High SPRED2 expression shows unfavorable associations in KIRP, ACC and LGG, but favorable associations in KIRC, SCLC and THCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SPRED2 RNA expression.
This table summarizes SPRED2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SPRED2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPRED2 shows lower tumor expression in KICH and UCEC and higher tumor expression in HNSC, STAD, PAAD and KIRC. The HNSC box plot shows higher SPRED2 RNA expression in tumor versus normal tissue (log2 FC = +0.881, t-test p < 0.001).
This table shows molecular features associated with SPRED2 in patient tissues and cancer cell lines. In patient samples, SPRED2 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SPRED2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
